Neurogene INC 10-Q quarterly reports

Neurogene Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased R&D expenses and net losses, while highlighting positive long-term clinical data for its lead candidate, NGN-401.

Neurogene Inc. reported increased net losses for Q3 2025, while advancing its NGN-401 Rett syndrome program with positive interim clinical data and maintaining a strong cash position.

Neurogene Inc. reported increased net losses for the first half of 2025, driven by higher R&D expenses for its NGN-401 Rett syndrome program, while securing FDA alignment for its registrational trial and initiating an ATM equity offering.

Neurogene Inc. reports a net loss of $22.6 million for Q1 2025, provides updates on its NGN-401 clinical trial for Rett syndrome, and discusses its strategic direction.

Neurogene Inc. released its Q3 2024 financial results, highlighting progress in its clinical programs, including positive interim data for NGN-401, and a recent $200 million private placement.

Neurogene Inc. reports a net loss of $35.4 million for the first six months of 2024, while advancing its gene therapy programs and manufacturing capabilities.

Neurogene Inc. reported a net loss of $16.9 million for the first quarter of 2024, while advancing its gene therapy programs for Rett syndrome and CLN5 Batten disease.